Table 1.
Study characteristics of each independent cohort.
| Centre | Country | Study design | Duration | Patients (n) | Field strengths (T) |
Manufacturer | Sequence | Histological criteria | Interval between MRE and biopsy (days), median (IQR) |
|---|---|---|---|---|---|---|---|---|---|
| Rochester28 | USA | Retrospective | January 2007 to March 2010 | 58 | 1.5 | GE | GRE | Brunt | 31 (9–40) |
| Yokohama10 | Japan | Prospective | July 2013 to April 2015 | 142 | 3.0 | GE | SE-EPI | NASH-CRN | 60 (24–121) |
| Incheon35 | Korea | Prospective | June 2017 to May 2020 | 82 | 3.0 | Siemens | SE-EPI | NASH-CRN | 1 (1–7) |
| Pittsburgh33 | USA | Prospective | October 2015 to December 2017 | 59 | 1.5 | GE | GRE | NASH-CRN | 82 (46–150) |
| Los Angeles34 | USA | Retrospective | May 2016 to March 2019 | 101 | 3.0 | Siemens | SE-EPI | NASH-CRN | 92 (39–158) |
| Seville42 | Spain | Prospective | November 2019 to December 2020 | 61 | 3.0 | Philips | GRE | SAF | 77 (38–119) |
| San Diego11,12,36-40 | USA | Prospective | January 2012 to Jane 2020 | 233 | 3.0 | GE | GRE | NASH-CRN | 34 (14–71) |
| Uppsala43 | Sweden | Prospective | March 2017 to December 2019 | 62 | 3.0 | GE | SE-EPI | SAF | 56.5 (37–79) |
GRE, gradient-echo sequence; CRN, Clinical Research Network; SAF, steatosis–activity–fibrosis; SE-EPI, spin-echo echo-planar imaging.